SECONDARY LOSS OF EFFICACY OF GALCANEZUMAB IN CHRONIC MIGRAINE WITH TRIPTAN OVERUSE: A CASE REPORT
Abstract
Galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is an effective preventive therapy for chronic migraine. However, some patients may exhibit a transient response followed by clinical deterioration. We present the case of a 44-year-old woman with chronic migraine and triptan overuse who initially responded well to galcanezumab but experienced a secondary loss of efficacy by the third month of treatment. The case underscores the importance of recognizing medication overuse as a modifier of treatment outcomes and highlights the need for combination strategies in complex migraine cases.
References
1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
2. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609. doi:10.1111/j.1468-2982.2009.01941.x
3. Pellegrino ABW, Davis-Martin RE, et al. Perceived triggers of primary headache disorders: a meta-analysis. Cephalalgia. 2018;38(6):1188-1198. doi:10.1177/0333102417752110
4. Panconesi A. Alcohol and migraine: trigger factor, consumption, mechanisms. J Headache Pain. 2008;9(1):19–27. doi:10.1007/s10194-008-0023-6
5. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12(10):575–583. doi:10.1038/nrneurol.2016.127
6. Gori S, Lucchesi C, Baldacci F, et al. Sleep and headache: clinical implications and therapeutic approaches. J Headache Pain. 2015; 16:92. doi:10.1186/s10194-015-0572-y
7. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the REGAIN study. Neurology. 2018;91(24):e2211-e2221. doi:10.1212/WNL.0000000000006640
8. Negro A, Curto M, Lionetto L, et al. Real-life data on the efficacy and safety of galcanezumab. J Headache Pain. 2020;21(1):72. doi:10.1186/s10194-020-01139-6
9. Holle-Lee D, Gaul C, Möller S, et al. Real-world evidence of switching anti-CGRP monoclonal antibodies. J Headache Pain. 2023;24(1):29. doi:10.1186/s10194-023-01545-4
10. Tepper S, Ashina M, Reuter U, et al. Long-term safety and efficacy of erenumab. Cephalalgia. 2020;40(6):543-553. doi:10.1177/0333102419889801
11. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine. Eur J Neurol. 2009;16(9):968–981. doi:10.1111/j.1468-1331.2009.02748.x
12. Boudreau GP, Dayno JM. Dose-ranging considerations for CGRP monoclonal antibodies. Headache. 2022;62(3):369-374. doi:10.1111/head.14267
13. Raffaelli B, Kalantzis R, Mecklenburg J, et al. Efficacy and tolerability of erenumab in patients with psychiatric comorbidities. J Headache Pain. 2021;22(1):24. doi:10.1186/s10194-021-01230-8
14. Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485-1495. doi:10.1016/S0140-6736(20)32160-7
15. Blumenfeld AM, Silberstein SD, Dodick DW, et al. OnabotulinumtoxinA for chronic migraine: PREEMPT 24-week pooled analysis. Cephalalgia. 2018;38(3):476–488. doi:10.1177/0333102417709998
16. Grazzi L, Raggi A. Cognitive behavioral therapy and biofeedback in migraine prophylaxis: a narrative review. Neurol Sci. 2021;42(Suppl 1):211–215. doi:10.1007/s10072-020-04545-8
